All News
Filter News
Found 262 articles
-
SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
11/12/2019
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced financial results for the third quarter ended September 30, 2019, and provided an update on recent company developments.
-
BeiGene Reports Third Quarter 2019 Financial Results
11/12/2019
BeiGene, Ltd. reported recent business highlights, anticipated upcoming milestones, and financial results for the third quarter and first nine months of 2019.
-
Rallybio Expands Leadership Team and Strengthens Drug Acquisition Capabilities
10/31/2019
These leadership appointments further advance Rallybio’s mission to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders.
-
Clinical Catch-Up: October 21-25
10/28/2019
Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look. -
SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN)
10/24/2019
SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in the Phase 2b ReNeu clinical trial evaluating mirdametinib, an oral, small molecule designed to inhibit MEK1 and MEK2, in children and adult patients with neurofibromatosis type 1 -associated plexiform neurofibromas
-
BioSpace Global Roundup, Sept. 26
9/26/2019
Companies from across the globe share updates on their business and pipelines. -
European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma
9/25/2019
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the European Commission has granted Orphan Drug Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of soft tissue sarcoma.
-
Edgewise Therapeutics Closes $50 Million Series B Financing
9/17/2019
Financing to Support Advancing Company’s Lead Product Candidate for Muscular Dystrophy
-
SpringWorks Therapeutics Announces Pricing Of Initial Public Offering
9/12/2019
SpringWorks Therapeutics, Inc. announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $18.00 per share.
-
SpringWorks Therapeutics Receives Breakthrough Therapy Designation for Nirogacestat for the Treatment of Adult Patients with Progressive, Unresectable, Recurrent or Refractory Desmoid Tumors
8/29/2019
SpringWorks Therapeutics, Inc. announced the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.
-
The company is seeking the funds to continue to drive the development of its lead candidates, nirogacestat, a gamma-secretase inhibitor for the treatment of desmoid tumors and PD-0325901, a MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas.
-
BioSpace Movers & Shakers, Aug. 16
8/16/2019
Biopharma companies strengthen their executive ranks and boards with new additions. -
SpringWorks Therapeutics Announces Appointment of Frank Perier as Chief Financial Officer
8/15/2019
SpringWorks Therapeutics, Inc. announced the appointment of Francis (Frank) Perier, Jr. as Chief Financial Officer (CFO).
-
BioSpace Global Roundup, Aug. 8
8/8/2019
Biopharma companies from across the globe share business and development updates. -
European Commission Grants Orphan Drug Designation for SpringWorks Therapeutics’ MEK Inhibitor, Mirdametinib, for the Treatment of Neurofibromatosis Type 1
7/30/2019
SpringWorks Therapeutics, Inc. announced that the European Commission has granted Orphan Drug Designation for mirdametinib, an oral, small molecule inhibitor of MEK1 and MEK2, for the treatment of neurofibromatosis type 1.
-
SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma
6/27/2019
SpringWorks Therapeutics, Inc. announced that the company has entered into a clinical trial collaboration agreement with GlaxoSmithKline to evaluate SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat, in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen antibody-drug conjugate, belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.
-
The companies will combine their research expertise to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations, non-V600 B-RAF mutations, and RAF fusions.
-
BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor
6/18/2019
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the formation of MapKure, LLC,
-
SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1
6/3/2019
SpringWorks Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation for PD-0325901, an investigational, oral, small molecule inhibitor of MEK1 and MEK2, for the treatment of patients ≥ 2 years of age with neurofibromatosis type 1-associated inoperable plexiform neurofibromas that are progressing or causing significant morbidity.
-
Last year, China invested $2.8 billion in U.S. health care companies, a big jump from the $702.9 million in 2017.